392 results on '"Gintant, Gary A."'
Search Results
2. Improving the in Vivo QTc assay: The value of implementing best practices to support an integrated nonclinical-clinical QTc risk assessment and TQT substitute
3. Discovery of (R)-(3-fluoropyrrolidin-1-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)quinolin-2-yl)methanone (ABBV-318) and analogs as small molecule Nav1.7/ Nav1.8 blockers for the treatment of pain
4. Automated blood sampling in canine telemetry studies: Enabling enhanced assessments of cardiovascular liabilities and safety margins
5. Repolarization studies using human stem cell-derived cardiomyocytes: Validation studies and best practice recommendations
6. Drug-induced QT prolongation: Concordance of preclinical anesthetized canine model in relation to published clinical observations for ten CiPA drugs
7. Electrophysiological characterization of drug response in hSC-derived cardiomyocytes using voltage-sensitive optical platforms
8. Assessing cardiac safety in oncology drug development
9. International Multisite Study of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment
10. CiPA challenges and opportunities from a non-clinical, clinical and regulatory perspectives. An overview of the safety pharmacology scientific discussion
11. Comprehensive In Vitro Proarrhythmia Assay (CiPA) Update from a Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA Meeting
12. Drug-induced cardiac abnormalities in premature infants and neonates
13. Publisher Correction: Cross-site and cross-platform variability of automated patch clamp assessments of drug effects on human cardiac currents in recombinant cells
14. Cross-site and cross-platform variability of automated patch clamp assessments of drug effects on human cardiac currents in recombinant cells
15. Statistical Applications in Design and Analysis of In Vitro Safety Screening Assays
16. A novel intravenous vehicle for preclinical cardiovascular screening of small molecule drug candidates in rat
17. The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative — Update on progress
18. Human ex-vivo action potential model for pro-arrhythmia risk assessment
19. The Cardiac Safety Research Consortium enters its second decade: An invitation to participate
20. In Vitro Early Safety Pharmacology Screening: Perspectives Related to Cardiovascular Safety
21. Drug-Induced Prolongation of the QT Interval: Present and Future Challenges for Drug Discovery
22. A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay Paradigm
23. Use of Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes in Preclinical Cancer Drug Cardiotoxicity Testing: A Scientific Statement From the American Heart Association
24. Preclinical Drug Safety and Cardiac Ion Channel Screening
25. Rechanneling the cardiac proarrhythmia safety paradigm: A meeting report from the Cardiac Safety Research Consortium
26. Can non‐clinical repolarization assays predict the results of clinical thorough QT studies? Results from a research consortium
27. The evaluation and management of drug effects on cardiac conduction (PR and QRS Intervals) in clinical development
28. Assessment of drug-induced increases in blood pressure during drug development: Report from the Cardiac Safety Research Consortium
29. Integrated and translational nonclinical in vivo cardiovascular risk assessment: Gaps and opportunities
30. How do the top 12 pharmaceutical companies operate safety pharmacology?
31. Characterization of A-935142, a hERG enhancer, in the presence and absence of standard hERG blockers
32. Stem Cell-Derived Models for Safety and Toxicity Assessments: Present and Future Studies in the “Proclinical Space”
33. Cardiac
34. Ventricular rate adaptation: A novel, rapid, cellular-based in-vitro assay to identify proarrhythmic and torsadogenic compounds
35. An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation
36. Assessing the fidelity of translation of non‐clinical assays: a Pharma perspective
37. The Challenges of Predicting Drug-Induced QTc Prolongation in Humans
38. Statistical Applications in Design and Analysis of In Vitro Safety Screening Assays
39. Cardiac Sodium Current (Nav1.5)
40. A novel secretagogue increases cardiac contractility by enhancement of L-type Ca2+ current
41. Electrophysiologic characterization of a novel hERG channel activator
42. In Vitro Early Safety Pharmacology Screening: Perspectives Related to Cardiovascular Safety
43. Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics
44. Preclinical Torsades-de-Pointes Screens: Advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic risk
45. Drug-induced QT prolongation: Concordance of preclinical canine model in relation to clinical outcome
46. The effects of plasma proteins on delayed repolarization in vitro with cisapride, risperidone, and d, l-sotalol
47. Functional consequences of methionine oxidation of hERG potassium channels
48. Gaining Efficiency in Clinical Trials With Cardiac Biomarkers
49. Challenges of Predicting Drug-Induced QTc Prolongation in Humans.
50. ILSI-HESI cardiovascular safety subcommittee initiative: Evaluation of three non-clinical models of QT prolongation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.